Rennova Health, Inc. · OTC:RNVA
Rennova Health — Investor Presentation (December 2015)
17 slides from Rennova Health's investor presentation, Dec 1, 2015
Slide 1: Rennova Health: Solutions Driven By Innovation
RennevaHealth Solutions Driven By Innovation Nasdaq: RNVA
Slide 2: Forward looking Statements and Non-GAAP Information
Forward looking Statements and Non-GAAP Information This presentation includes forward-looking statements about Rennova Health’s anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans, obj
Slide 3: Nasdaq listing after Medytox and CollabRx merger
NASDAQ: RNVA Listed on Nasdaq on November 3rd 2015 after completion of a merger between Medytox Solutions, Inc. and CollabRx, Inc. Expert Systems for Precision Medicine OTCBB since 2011 (MMMS) Nasdaq listed since 1995 CollabRx since 2012 (CLRX) • We are four years into our business plan with a numbe
Slide 4: Vertically integrated diagnostics company with five laboratories
Rennova Health, Inc. is a vertically integrated company that provides industry leading Diagnostics and supportive software solutions to healthcare providers. Rennova Health owns and operates five high-complexity CLIA and CAP certified laboratories strategically located across the U.S International T
Slide 5: Single source solution for Medical Providers
Rennova Health, Inc. offers a single source solution for Medical Providers The diagnostics sector has changed dramatically in the last few years Medical providers need more than just diagnostics They need: Rennova products: Efficient and easy ordering and reportingMedytox Advantage Electronic health
Slide 6: Our Brands
Our Brands Our solutions can be stand alone or integrated 6
Slide 7: Our Brands: product descriptions
CollabRx enables efficient interpreta:on of diagnos:cs results into meaningful and useful informa:on. StableSpot is a proprietary collec:on device that simplifies collec:on and Pain Management transporta:on of a pa:ent Medytox Advantage is a Interpreta:on: Behavioral Health proprietary ordering and blo
Slide 8: Drug and Alcohol Rehabilitation and Pain Management markets
Drug and Alcohol Rehabilitation •Total Market Size – estimated at $35 Billion* •Large and growing number of facilities in a fragmented market •Between 14,500 to 16,700 outpatient clinics* •Market growth from high demand: •Over 23 million Americans are addicted to alcohol and other drugs** •The numbe
Slide 9: History
History Revenue of $57.93M Pre-merger numbers ADJUSTED from Medytox Revenue of EBITDA $41.89M $18.18M 2015 AJUSTED EBITDA 2014 Revenue of $14.33M $21.08M 2013 ADJUSTED EBITDA $4.18M Revenue of $3.99M 2012 ADJUSTED Grew lab services EBITDA organically -$621K Expanded lab Focused on Merger and Nasdaq
Slide 10: 2015 Revenue 9 months: $42.6M
2015 Revenue 9 months: $42.6M Diagnostics represents >95% of our revenue Jan-Sept 2015 $45,000,000 Transition year $42,220,000 $40,000,000 • Investment in Labs $35,000,000 • Investment in software $30,000,000 • Merger costs $25,000,000 • Billing Company restructure $20,000,000 • Toxicology sector •
Slide 11: Capital Structure
Capital Structure 13,763,275 common shares outstanding as of 11/19/2015 Preference Shares 5,000 shares of Series B Preference shares These shares convert to 1,146,789 additional shares of common stock on Dec 31st each year for five years Total = 5,733,945 additional common shares over five years $36
Slide 12: Management
Management: • Seamus Lagan CEO 20 years experience in the restructuring, development and management of startup and small companies • Jason Adams CFO CFO in behavorial health sector and Senior Financial Management of public companies • Sebastien Sainsbury Investor Relations Banking and wealth managem
Slide 13: Board
Board: • Thomas Mika Chairman of Rennova, CEO of CollabRx (subsidiary) 10 years as Chairman and CEO of a Nasdaq listed Company. Oversaw a number of public offerings. Holds a Bachelor of Science degree in Microbiology, MBA Harvard • Seamus Lagan CEO 20 years experience in the restructureing, developm
Slide 14: Foundation to grow from
Foundation to grow from …we are able to grow our core diagnostics business from a position of strength and to expand into the more complex, higher-margin clinical diagnostics ... we can agressively acquire the customers, licenses or business of cash- strapped, failing diagnostic labs of all sizes ..
Slide 15: Current focus
Current focus Expand our current lab business accross the nation Ongoing Capitalize on the disruption in the toxicology industry Ongoing Add additional tests and methodologies to our menu Ongoing Roll out our EHR product Launched Oct Roll out our Medical Billing Services Launch underway Implement ou
Slide 16: Reconciliation of GAAP to Adjusted Measures - Medytox Solutions, Inc. Pre Merger
Reconciliation of GAAP to Adjusted Measures - Medytox Solutions, Inc. Pre Merger (in thousands) 2011 2012 2013 2014 Jan-Sep 2015 Net Revenue $ 3,993 $ 21,076 $ 41,889 $ 57,928 $ 28,921 Write-off of receivables aged greater than one year - - - - 13,299 Adjusted Revenue $ 3,993 $ 21,076 $ 41,889 $ 57,
Slide 17: Contact Us
Contact Us Rennova Health, Inc. 400 South Australian Avenue 8th Floor West Palm Beach, FL 33401 Phone: 844-RENNOVA Email: info@rennovahealth.com www.rennovahealth.com 17
Rennova Health — Investor Presentation (December 2015) on 6ix